In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, many questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch tracking series will examine how the perception and performance of Ocrevus evolves through Year 1 with an MS prescriber base that has hitherto struggled to treat PP-MS.

What you will learn in this content

  • What is the awareness of, familiarity with, and perceptions related to Ocrevus among U.S. neurologists?
  • For which patients are neurologists prescribing Ocrevus, what are the reasons for prescribing, and how satisfied are they with Ocrevus?
  • What promotional messages and activities are Genentech/Roche employing in support of the Ocrevus launch in PP-MS?
  • How does the trial and adoption of Ocrevus in PP-MS compare to Ocrevus and other recent product launches in the saturated relapsing MS market? How do adopters and nonadopters in PP-MS compare across key metrics?

Product description

Launch Tracking: Ocrevus Wave 1 (US) Primary Progressive Multiple Sclerosis is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Ocrevus PP-MS Launch Tracking Wave 1 (US)
    • Key Findings
      • Benchmarking Ocrevus Launch Success vs. Other Launched Drugs
        • Uptake of Ocrevus in PP-MS Is Impressive at One Month Postlaunch
      • Prescriber and Nonprescriber Profiles
        • Differences Between Ocrevus Prescribers and Nonprescribers for PP-MS
        • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Awareness and Perceptions
        • Unaided and Aided Awareness of Ocrevus
          • Awareness of Ocrevus One Month Postlaunch Is Substantial
          • Unaided Awareness of Drugs Approved or Launched for the Treatment of MS
          • Aided Awareness of Ocrevus
          • Aided Awareness of Ocrevus's Indication
          • Aided Awareness of Ocrevus's Mechanism of Action
          • Aided Awareness of Ocrevus's Dosing Interval
          • Aided Awareness of the Comparator Used in Ocrevus's Pivotal Clinical Trials in PP-MS
          • Aided Awareness of Ocrevus's Clinical Profile in PP-MS
        • Familiarity with Ocrevus
          • Few Neurologists Are Unfamiliar with Ocrevus
          • Level of Familiarity with Ocrevus
        • Sources of Familiarity with Ocrevus
          • Word of Mouth from Neurologist Colleagues Aids Familiarity with Ocrevus
        • Initial Reaction to and Interest in Ocrevus
          • Neurologists with a Favorable Impression of Ocrevus Express Interest to Learn More
          • Ocrevus Product Profile in PP-MS
          • Ocrevus Information Requiring Additional Education
          • Initial Reaction of Neurologists to Ocrevus for the Treatment of PP-MS
          • Neurologists' Level of Interest in Learning More About Ocrevus
        • Impressions of Ocrevus
          • Surveyed Neurologists' Favorable Impression of Ocrevus's Efficacy in PP-MS Outweighs Perceptions of Risk
          • Unaided Advantages of Ocrevus for PP-MS
          • Unaided Disadvantages of Ocrevus for PP-MS
          • Statement Agreements About Ocrevus for PP-MS
          • Statement Agreements About Ocrevus for PP-MS: Mean Rating
          • Rating of Ocrevus's Risk-Benefit Balance for PP-MS
        • Prescriber and Nonprescriber Profiles
          • Ocrevus Nonprescribers Appear More Risk-Averse Than Prescribers
          • Differences Between Ocrevus Prescriber and Nonprescriber Profiles
      • Ocrevus Trial and Use
        • Willingness to Prescribe Ocrevus
          • Efficacy Drives High Willingness to Prescribe Ocrevus to PP-MS Patients
          • Willingness to Prescribe Ocrevus to PP-MS Patients
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in PP-MS
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Ocrevus in PP-MS: Mean Rating
        • Number of Patients Currently Receiving Ocrevus
          • Two-Thirds of Neurologists Have Already Prescribed Ocrevus to PP-MS Patients at One Month Postlaunch
          • Number of PP-MS and Nonrelapsing SP-MS Patients Prescribed Ocrevus
          • Mean Number of PP-MS and Nonrelapsing SP-MS Patients Prescribed Ocrevus
          • Ocrevus Discontinuation Rate in PP-MS
          • Ocrevus Discontinuation Rate in PP-MS Patients: Mean Number
          • Reasons for Discontinuing Ocrevus
          • Current Use of DMTs in PP-MS Patients
          • PP-MS Patient Inquiries About Ocrevus
          • PP-MS Patient Inquiries About Ocrevus: Mean Number
          • Percentage of PP-MS Patients Starting Ocrevus Following a Request
          • Categories of Current Ocrevus-Treated PP-MS Patients
          • Source Therapy for Current PP-MS Patients Switched to Ocrevus
          • Number of Prior Therapies for PP-MS Patients Switched to Ocrevus
          • Reasons for Starting/Switching to Ocrevus in PP-MS
          • Ocrevus Follow-Up Visits in PP-MS
          • Ocrevus Treatment Response in PP-MS
          • Ocrevus-Prescribed PP-MS Patients' Experience with Infusion Reactions
        • Reasons for Not Yet Prescribing Ocrevus
          • Safety Concerns, Familiarity, and Cost to Patients Are the Major Dampers on Ocrevus Uptake in PP-MS
          • Reasons for Not Yet Prescribing Ocrevus to PP-MS Patients
          • Obstacles to Prescribing Ocrevus to PP-MS Patients
        • Anticipated Ocrevus Use
          • Wave 1 Respondents Project That Ocrevus Will Rapidly Become the Patient-Share Leader in PP-MS
          • Anticipated Timing for Ocrevus Prescribing to PP-MS Patients Among Current Nonprescribers
          • Percentage of PP-MS and Nonrelapsing SP-MS Patients Considered Ocrevus Candidates
          • Percentage of PP-MS Patients Considered Ocrevus Candidates by Treatment Situation
          • Current and Anticipated DMT Treatment Rates in PP-MS
          • Current and Anticipated DMT Treatment Rates in PP-MS: Mean
          • Current and Anticipated Brand Allocation Among DMT-Treated PP-MS Patients
        • Ocrevus Performance on Key Attributes
          • Surveyed Neurologists Report Early Satisfaction on Key Ocrevus Attributes
          • Prescribers' Overall Satisfaction with Ocrevus in PP-MS
          • Current Reimbursement Limitations on Ocrevus for PP-MS
          • Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in Treating PP-MS
          • Mean Rating of Ocrevus's Performance on Clinical and Nonclinical Attributes in Treating PP-MS
      • Effectiveness of Face-to-Face Detailing for Ocrevus
        • Ocrevus Sales Representative Frequency and Reach
          • Nearly One-Quarter of Neurologists Met with an Ocrevus Sales Representative Within the Month Preceding Survey Fielding
          • Ocrevus Sales Representative Detailing Reach
        • Satisfaction with Ocrevus Sales Representative
          • Neurologists Are Highly Satisfied with Ocrevus Sales Representatives
          • Neurologist Satisfaction with Ocrevus Sales Representatives
          • Neurologist Satisfaction with Ocrevus Sales Representatives: Mean Rating
        • Ocrevus Message Recall
          • Ocrevus's Approval for PP-MS is a Key Message in Early Detailing Efforts
          • Unaided Ocrevus Message Recall During Recent Detail
          • Aided Ocrevus Message Recall During Recent Detail
      • Methodology
        • Primary Market Research Methodology
        • State Location of Practice
        • U.S. Region of Practice
        • Practice Setting
        • Practice Location
        • Years in Practice Postresidency
        • Patient Allocation by MS Disease Classification
        • Current DMT Treatment Rate in PP-MS Patients
      • Appendix
        • Abbreviations
        • Bibliography

    Author(s): Sarah Soucy; Jonathan Searles

    Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.

    Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism

    Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.


    Related Reports

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details